A recently published Phase 4 head-to-head trial has evaluated the tolerability of Sanofi’s Nuvaxovid (recombinant protein technology) against Moderna’s mNexspike... Read more
Clinical trial highlights tolerability advantages of protein-based vaccine
21/04/2026
Published by vivi
